Forbion Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
16
- Investments
-
163
- Portfolio
-
34
- Exits
-
78
Forbion General Information
Description
Founded in 2006, Forbion is a venture capital firm headquartered in Naarden, Netherlands. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, the firm selects investments that will positively affect the health and well-being of patients. The firm also operates a joint venture with BioGeneration Ventures, which manages three separate seed and early-stage funds focused on Benelux and Germany.
Contact Information
Website
www.forbion.com
Year Founded
2006
Investor Status
Actively Seeking New Investments
Trade Association
Dutch Venture Capital Association (NVP)
Principles for Responsible Investment (PRI)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Impact Investing
Primary Office
- PO Box 5187
- 1410 AD Naarden
- Netherlands
+31 035 000 0000
Forbion Investments (163)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| VectivBio | 29-Jun-2022 | PIPE | 0000 | Biotechnology | Generating Revenue | |
| 00000000 | 12-Apr-2022 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 3 | 00000-000 000000 00 |
| 00000000 | 16-Mar-2022 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 000000 000 00.0 |
| 0000000000 0000000 | 09-Mar-2022 | 00000 00000 | 00.000 | Drug Discovery | Generating Revenue | 00000-000 000000 00 |
| 0000000000 0000000 | 23-Feb-2022 | 0000 00000 | 00.000 | Biotechnology | Generating Revenue | |
| 0000000 | 23-Dec-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | 000000 000 00.0 |
| 00000 000000 | 20-Dec-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 00000-000 000000 00 |
| 00000000 000000000 | 17-Dec-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 000000 00000000 |
| Rectify (Drug Discovery) | 14-Oct-2021 | Early Stage VC | 0000 | Drug Discovery | Generating Revenue | 00000 0000000 00.0 |
| Oxitope Pharma | 20-Aug-2021 | Seed Round | 00.000 | Pharmaceuticals | Startup | 00000 0000000 00.0 |
Forbion Exits (78)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Gyroscope | 22-Feb-2022 | Merger/Acquisition | 00000 |
| 0000000 00000000 0 | 10-Dec-2021 | 000 | 00000 |
| 00000000 000000000 | 31-Mar-2021 | 000 | 00000 |
| 0000 000000000000 | 21-Jan-2021 | 000000 0000000000 | 00000 |
| 0000000000 0000000 | 07-Oct-2020 | 000000000 00000 00 | 000.00 |
| 000000000 | 18-Sep-2020 | 000000000000000000 | 00000 |
| 0000 000000000000 | 17-Sep-2020 | 000 | 00000 |
| 00000 000000000000 | 09-Sep-2020 | 000000000000000000 | 00000 |
| Promedior | 13-Feb-2020 | Merger/Acquisition | 00000 |
| Ario Pharma | 01-Oct-2019 | Out of Business |
Forbion Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Forbion Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Forbion Team (46)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Vincent Van Houten | Chief Financial Officer & General Partner | 0 | 0 | 0 | Naarden, Netherlands |
| Martien van Osch | Co-Founding Partner & Managing Partner | 00 | 0 | 0 | Naarden, Netherlands |
| Geert-Jan Mulder MD | Managing Partner and Co-Founding Partner | 00 | 0 | 0 | Naarden, Netherlands |
| Sander Slootweg | Co-Founder & Managing Partner & Board Member | 0 | 0 | 0 | Naarden, Netherlands |
| Holger Reithinger Ph.D | General Partner | 00 | 0 | 0 | Munich, Germany |
Forbion Co-Investors (115)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| BioGeneration Ventures | 6 | 0 |
|
|
|
| Novartis Venture Fund | 0 | 0 | 0 |
|
|
| Novo Holdings | 0 | 0 |
|
|
|
| Fountain Healthcare Partners | 0 | 0 | 0 |
|
|
| OrbiMed | 0 | 0 | 0 |
|
|